CollPlant Biotechnologies Ltd - Ordinary Shares New
CLGN
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.91M
Close$
$-0.11
102.7% downside
Current Fair Value
102.7% downsideOvervalued by 102.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.91 Million |
|---|---|
| Enterprise Value | $4.30 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-9.4 |
| Beta | 0.74 |
| Outstanding Shares | 1,374,720 |
Return
| Return on Equity | -268.81% |
|---|---|
| Return on Assets | -143.03% |
| Return on Invested Capital | -191.75% |
Valuation & Multiples
| P/E Ratio | -0.44 |
|---|---|
| PEG | -0.39 |
| Price to Sales | - |
| Price to Book Ratio | 1.37 |
| Enterprise Value to Revenue | 11.05 |
| Enterprise Value to EBIT | -0.33 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.62 |
| Debt to Equity | 0.54 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 31, 2026
EPS Estimate
$-0.24
Average shareholder expectationRevenue Estimate
$480,000
Average shareholder expectationNext Earnings Call
Expected Date
December 2, 2026
EPS Estimate
$-0.24
Average shareholder expectationRevenue Estimate
$480,000
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.00%0% |
|---|---|
| Total Invested | $25▼ 34.21% |
| Investors Holding | 10% |
ESG Score
No data
About CollPlant Biotechnologies Ltd
CEO: Yehiel Tal